Ascentage Pharma (AAPG) announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology, CSCO, Guidelines. Lisaftoclax, APG-2575, the company’s investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. Olverembatinib, the company’s novel next-generation tyrosine kinase inhibitor, received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, and retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies. As the world’s second Bcl-2 inhibitor to submit a New Drug Application and the first China-developed Bcl-2 inhibitor to submit an NDA and receive Priority Review designation in China, lisaftoclax, supported by its robust clinical data, has been recommended in the CSCO 2025 Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies, as a monotherapy for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In the CSCO 2025 Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, the recommendation for olverembatinib for the treatment of children with Ph+ ALL who harbor the T315I BCR-ABL1 kinase domain mutation was upgraded to Level I.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma reports FY24 EPS (RMB 1.34) vs. (RMB 3.28) last year
- Ascentage Pharma sees cash runway through 2027
- Ascentage Pharma initiated with an Overweight at JPMorgan
- Ascentage Pharma to Announce 2024 Financial Results and Corporate Update
- Ascentage Pharma says olverembatinib granted BTA by China’s CDE